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Abstract
Background: Tumor necrosis factor-α (TNF-α) is an immunostimulatory cytokine that is consistently high in the
breast tumor microenvironment (TME); however, its differential role in mitochondrial functions and cell survival in
ER/PR +ve and ER/PR −ve breast cancer cells is not well understood.
Methods: In the current study, we investigated TNF-α modulated mitochondrial proteome using high-resolution
mass spectrometry and identified the differentially expressed proteins in two different breast cancer cell lines, ER/PR
positive cell line; luminal, MCF-7 and ER/PR negative cell line; basal-like, MDA-MB-231 and explored its implication in
regulating the tumorigenic potential of breast cancer cells. We also compared the activity of mitochondrial
complexes, ATP, and ROS levels between MCF-7 and MDA-MB-231 in the presence of TNF-α. We used Tumor
Immune Estimation Resource (TIMER) webserver to analyze the correlation between TNF-α and mitochondrial
proteins in basal and luminal breast cancer patients. Kaplan-Meier method was used to analyze the correlation
between mitochondrial protein expression and survival of breast cancer patients.
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Results: The proteome analysis revealed that TNF-α differentially altered the level of critical proteins of
mitochondrial respiratory chain complexes both in MCF-7 and MDA-MB-231, which correlated with differential
assembly and activity of mitochondrial ETC complexes. The inhibition of the glycolytic pathway in the presence of
TNF-α showed that glycolysis is indispensable for the proliferation and clonogenic ability of MDA-MB-231 cells (ER/
PR −ve) as compared to MCF-7 cells (ER/PR +ve). The TIMER database showed a negative correlation between the
expressions of TNF-α and key regulators of mitochondrial OXPHOS complexes in basal breast vs lobular carcinoma.
Conversely, patient survival analysis showed an improved relapse-free survival with increased expression of
identified proteins of ETC complexes and survival of the breast cancer patients.
Conclusion: The evidence presented in our study convincingly demonstrates that TNF-α regulates the survival and
proliferation of aggressive tumor cells by modulating the levels of critical assembly factors and subunits involved in
mitochondrial respiratory chain supercomplexes organization and function. This favors the rewiring of
mitochondrial metabolism towards anaplerosis to support the survival and proliferation of breast cancer cells.
Collectively, the results strongly suggest that TNF-α differentially regulates metabolic adaptation in ER/PR +ve (MCF-
7) and ER/PR −ve (MDA-MB-231) cells by modulating the mitochondrial supercomplex assembly and activity.
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Introduction
Breast cancer is still a leading cause of death in women
worldwide [1], hence it requires a further understanding
of metabolic adaptations of different breast cancer sub-
types, for the identification of alternative or novel drug
targets. Broadly, breast cancer has been categorized as
hormone-responsive ER/PR +ve representing an early
benign tumor condition, whereas ER/PR −ve as aggres-
sive and metastasis at a late stage. The tumor micro-
environment (TME) of a solid tumor is complex and
constitutes many different cell types including the re-
cruitment of circulating monocytes and its differenti-
ation to tumor-associated macrophage (TAM) [2]. The
interaction of TAMs and breast cancer cells lead to an
inflammatory milieu in TME which reprograms the gen-
etic expression landscape of tumor cells leading to im-
mune evasion and tumor progression. The mechanisms
regulating these processes are emerging, however not
well understood.
Inflammation in TME enhances tumor growth and
metastasis in cancers of different origin like pancreatic,
lung, and gastric [3–6] including breast cancer. Inflamma-
tion affects all phases of malignancy, including proliferation
at the early stage, angiogenesis, progression, and tumor
metastasis [7, 8]. The increased levels of several pro-
inflammatory cytokines like TNF-α, IL-8, IL-10, and growth
factors like TGF-β have been observed in the tumor micro-
environment [8–10]. Despite the close association between
inflammation and tumorigenesis, the mechanisms under-
lying the cytokine-mediated metabolic adaption and its
impact on regulating the tumorigenic potential of breast
cancer cells is not well understood.
TNF-α is a pleiotropic cytokine and acts as pro- or
anti-tumorigenic depending on the type and stage of
specific cancer. TNF-α level is high in tumors of
different origin including breast cancer. Moreover, stud-
ies in the last decade had shown that mitochondria are
emerging as a platform for assembly of the complexes
regulating the NF-κB and IFN pathways, hence innate
immunity during viral infections. Previously, we have re-
ported that adaptor proteins like STING and NLRX1
localize to mitochondria and its contact site, which be-
yond their role in innate immunity, can act as tumor
suppressor and modulate mitochondrial functions in the
presence of TNF-α [11, 12]. This evidences suggest that
mitochondria act as a signaling hub for integrating in-
flammatory and metabolic cues; however, their role in
maintaining cancer cell metabolism and regulating the
overall tumor growth within the altered cytokine milieu
of a TME, needs to be further investigated. In the
current study, we systematically investigated the TNF-α
modulated mitochondrial proteome by employing quan-
titative mass spectrometry. We observed that TNF-α
differentially modulate the subunits of oxidative phos-
phorylation (OXPHOS) complexes and mitochondrial
functions to regulate the clonogenic and migration abil-
ities of the breast cancer cells.
Materials and methods
Cell Lines used and the reagents
MCF-7 and MDA-MB-231 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM, Life Technologies, Carls-
bad, CA, USA) media were supplemented with 10% v/v
heat-inactivated fetal bovine serum (Life Technologies) 1%
penicillin, streptomycin, and neomycin (PSN) antibiotic mix-
ture (Life Technologies). Human TNF-α (premium grade)
was purchased from MiltenylBiotec GmbH, Germany.2-de-
oxy-glucose, NAC (N-Acetyl Cysteine) were purchased from
Sigma-Aldrich, USA. CM-H2DCFDA and MitoSOX
TM Red
were purchased from Molecular Probes Inc., USA.
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Mitochondria isolation and quality control
Cells were seeded at 3 × 106 density and after overnight
incubation cells were treated as indicated. The cells were
collected and passed through 24-G × 1″ syringe 50–60
times using Sucrose-Tris mitochondria isolation buffer
(0.25 M Sucrose, 10 mM Tris HCl, and 1X protease in-
hibitor). After centrifugation at 600×g for 10 min, the
supernatant was collected and centrifuged at 8000×g.
The obtained pellet (mitochondrial fraction) was washed
thrice with the isolation buffer and lysed in RIPA lysis
buffer. Purity of mitochondrial fraction was checked by
western blotting using antibodies against Actin, Tom20,
SDHA, and UQCRC2.
Sample preparation and digestion
Isolated mitochondrial fractions were lysed in RIPA lysis
buffer (Thermo Scientific, Rockford, IL, USA) with
protease inhibitor (Roche Diagnostics, Mannheim,
Germany) and phosphatase inhibitor cocktail (Roche
Diagnostics), followed by a brief sonication on ice. The
cells were sonicated and centrifuged for 15 min at 24,
000×g at 4 °C and the supernatant was transferred to a
new tube. Protein concentration was determined using
BCA assay kit (Thermo Scientific). Protein samples were
fractionated on 4–12% Bis-Tris Gels (Invitrogen, Carlsbad,
CA, USA) and stained with Coomassie Brilliant Blue
(Sigma-Aldrich, St. Louis, MO, USA). Each gel lane was
cut into ten pieces and subjected to in-gel tryptic digestion
following the general protocol [13]. Briefly, protein bands
were excised, destained, washed, and further reduced with
20 mM DTT and alkylated with 55 mM iodoacetamide.
After dehydration, the proteins were digested with 13 ng/
ml sequencing-grade modified porcine trypsin (Promega,
Madison, WI, USA) in 50 mM ammonium bicarbonate
overnight at 37 °C. Peptides were extracted from the gel
slices in 50% (v/v) ACN and 5% (v/v) formic acid and
dried under vacuum.
Mass spectrometry analysis
Peptides were resuspended in 25 μL Solvent A (0.1% for-
mic acid in water, pH 2.0) and 5 μL sample was loaded
onto an analytic column (PepMap, 75 μm ID × 50 cm 3
μm, ES803, Thermo Fisher Scientific, San Jose, CA,
USA) interfaced with a nano-ultra-HPLC system
(EasynLC, Thermo Fisher Scientific) and separated with
a linear gradient of 5–32% Solvent B (0.1% formic acid
in ACN), time (B%) 0∼12 min (5% solvent B), 97 (40%),
105 (70%), 117 (70%), and 120 (2%), for 120 min at a
flow rate 300 nL/min. MS spectra were recorded on a
Q-Exactive Orbitrap mass spectrometer (Thermo Fisher
Scientific). The standard mass spectrometric condition
of the spray voltage was set to 2.2 kV and the
temperature of the heated capillary was set to 250 °C.
The full MS scans were acquired in the mass analyzer at
400–1400 m/z with a resolution of 70,000 and the MS/
MS scans were obtained with a resolution of 17,500 by
normalized collision energy of 27 eV for high-energy
collisional dissociation fragmentation. The automatic
gain control target was 1 × 105, the maximum injection
time was 120 ms, and the isolation window was set to
2.0 m/z. The Q-Exactive was operated in a data-
dependent mode with one survey MS scan followed by
ten MS/MS scans, and the duration time of dynamic
exclusion was 20 s.
Database search
Collected MS/MS data were searched against the decoy
UniProt human database (version 3.83, 186 578 entries)
by Proteome Discoverer 2.2 (PD 2.2, Thermo Scientific)
software. Precursor and fragment ion tolerance were set
to 10 ppm and 0.5 Da, respectively. Trypsin was chosen
as the enzyme with a maximum allowance of up to two
missed cleavages. Carbamidomethyl (+ 57.02) of cysteine
was considered as the fixed modification, while the vari-
able modification was set for methionine oxidation (+
15.99). The result filtration parameters of PD 2.2 were
set as follows: peptide and protein identifications were
accepted if they could be established at greater than 95%
and 99% probability, respectively, as specified by the
Peptide and Protein Prophet algorithm and if the protein
identification contained at least two identified peptides
with a false discovery rate ≤ 0.1%.
Relative protein quantification and bioinformatics analysis
Relative protein quantitation was accomplished using
spectral counting. The MS/MS data were normalized to
compare the abundances of proteins between samples
using PD 2.2 software. The normalized spectral counts
from triplicate analyses of the MCF-7 and MDA-MB-
231 cells treated or untreated with TNF-α were com-
pared using the R program [14] with power-law global
error model (PLGEM; version 1.50.0) software used to
determine signal-to-noise ratio and P-value [15, 16]. We
filtered statistically significant differentially expressed
proteins (DEPs) using 0.01 as a p-value threshold. Then
we refined spectral count readouts for the proteins
within the range of 0.01≤ p-value ≤0.05 using the
Moment Adjusted Imputation (MAI) equation [17] to
identify DEPs with statistical significance with more sen-
sitivity. After the MAI refinements, we have determined
the p-value with PLGEM and filtered statistically
significant DEPs using 0.01 as a p-value threshold. The
subcellular localization and functional annotation of the
identified proteins were classified using Ingenuity Path-
way Analysis (IPA, QIAGEN Inc., Valencia, CA, US) and
Protein Analysis through Evolutionary Relationships
Classification System (PANTHER, version 7.2,) [18].
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Kaplan-Meier survival analysis was used to estimate
the association of the gene’s expression with survival of
patients.
BN-PAGE
MCF7 and MDA-MB231 cells were seeded at density 3
× 106/100 mm dish. After overnight incubation cells
were treated as required. Mitochondria from MCF-7 and
MDA-MB231 cells were isolated in Tris-Sucrose buffer
as described above and 50 μg pellets were solubilized as
per manufacturer’s protocol (Thermo Fisher Scientific)
and BN-PAGE was performed on Native PAGE Novex3%–
12% Bis-Tris Protein Gels (ThermoFisher Scientific). In-gel
enzyme activity of different OXPHOS complexes was
analyzed on gradient Bis-Tris gel.
Substrate: for complex I, 1 mg NADH and 25 mg NTB
was prepared in 2 mM Tris-HCl (pH 7.4), and for com-
plex IV, 5 mg DAB and 10 mg cytochrome C in 50 mM
potassium phosphate buffer (pH 7.4) was used for in-gel
activity. For complex III and complex IV combined, 10
mg 3,3′ diaminobenzidine tetrachloride (DAB) and 25
mg cytochrome C in 25 ml of 50 mM sodium phosphate
buffer (pH 7.2) was used.
Spectrophotometric analysis of mitochondrial complex I
and complex II assays
MCF-7 and MDA-MB-231 cells were seeded at the dens-
ity of 5 × 105 cells/well in the 6-well plate. The cells were
treated as indicated, harvested, and washed with cold
DPBS. The cells were subjected to 2–3 freeze-thaw cycles
in a freeze-thaw complete solution (0.25 M sucrose, 20
mM Tris-HCl (pH 7.4), 40 mM KCl, 2 mM EDTA supple-
mented with 1 mg/ml fatty acid-free BSA, 0.01% Digitonin
and 10% Percoll). The cells were washed again with the
freeze-thaw solution devoid of digitonin and resuspended
in complex I assay buffer (35 mM potassium phosphate
(pH 7.4), 1 mM EDTA. 2.5 mM NaN3,1 mg/ml BSA, 2
μg/ml antimycin A, 5 mM NADH). Complex I activity
was measured by monitoring the decrease in absorbance
at 340 nm after the addition of 2.5 mM acceptor decylubi-
quinone indicating the oxidation of NADH.
Similarly, for complex II activity, cells were seeded at a
density of 1.5 × 106/60 mm dish. The cells were
harvested and washed with cold DPBS. The cells were
suspended in 0.5 ml of 20 mM hypotonic potassium
phosphate buffer (pH 7.5) and lysed using a 24-G sterile
syringe and subjected to freeze-thaw cycle. The cell lys-
ate (80 μg) was added to the 1 ml of complex II assay
buffer (0.1 M potassium phosphate (pH 7.5), 50 mg/ml
BSA, 100 mM NaN3, 200 mM succinate) and incubated
at 37 °C. Complex II activity was measured for 6 min by
monitoring the decrease in absorbance at 600 nm after
the addition of 2.5 mM acceptor decylubiquinone and
DCPIP.
ATP assay
MCF-7 and MDA-MB-231 cells were seeded in a density
of 5 × 104 in 24 well plates. ATP levels were measured
in control and treatment conditions by an ATP
dependent luciferase assay using an ATP determination
kit (Molecular Probes/Life Technologies, ON, Canada).
Assay of intracellular and mitochondrial ROS
ROS levels and mitochondrial ROS were measured by
CM-H2DCFDA (10 μM) and MitoSOX
TM Red (5 μM)
staining, respectively. Briefly, MCF-7 and MDA-MB-231
cells were plated at the density of 1.5 × 105 cells/well in
24-well plates. The cells were treated and stained with
indicated reagent and monitored under a fluorescence
microscope (Olympus IX81 microscope; Olympus,
Tokyo, Japan). A minimum of 5 images and 80–100 cells
were used for analysis.
ROS levels were also quantified by fluorometry. Briefly,
MCF-7 and MDA-MB231 cells were treated and stained
with CM-H2DCFDA (12.5 μM) in DPBS for intracellular
ROS quantification and MitoSOX Red (2.5 μM) in DMEM
for mitochondrial ROS quantification. The cells were
washed with DPBS and normalized to1 × 106 cells/ml.
Fluorescence intensity was quantified by a fluorometer
(Hitachi High-Technologies Corp., Japan) with excitation/
emission at 495/520–540 nm and 510/570–600 nm,
respectively.
MTT assay
MCF-7 and MDA-MB-231 cells were seeded (5000 cells/
well) in 96-well plate. The cells were treated as indicated
and cell viability was determined using the standard
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
liumbromideassay. The purple formazan crystals were
dissolved in DMSO, transferred in a 96-well plate (100
μL/well) and the absorbance was recorded on a micro-
plate reader at a wavelength of 570 nm.
Clonogenic assay
MCF-7 and MDA-MB-231 cells (2000 cells/well) were
seeded in 6 well plates and treated as per requirements.
Cells were incubated till single clones were visible and
later were fixed using methanol and stained using 0.2%
crystal violet as described earlier [19].
Survival analysis
BRCA patients in The Cancer Genome Atlas (TCGA)
database were ranked by the level of NDUFB1, SDHA,
and COX7C expression and divided into two groups:
top quarter and low quarter in expression level. These
groups were analyzed in Kaplan-Meier survival plot to
estimate the correlation between the gene’s expression
level and survival of patients using OncoLnc [20].
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Scratch assay
Scratch assay was performed in MCF-7 and MDA-MB-
231 cells. Cells were seeded at a density of 2.5 × 105 cells
per well in 12 well plates. After overnight incubation
cells were treated and a vertical wound was created
using a sterile P200 micropipette tip. At zero time point,
images of each scratch were taken using Nikon Ti-2
eclipse inverted fluorescent microscope at × 10 and were
analyzed after 24 h of treatment. Migration rate was
measured using ImageJ software which measures open
area at a different time interval. The percentage of open
area in each condition was plotted.
Statistical analysis
Data are expressed as mean ± SEM of two or three in-
dependent experiments. Unpaired two-tailed Student’s
t-test was performed. GraphPad Prism was used to per-
form all statistical analyses.
Results
TNF-α differentially modulates mitochondrial proteome in
ER/PR +ve (MCF-7) and ER/PR −ve (MDA-MB-231) breast
cancer cells
To identify TNF-α modulated differentially expressed
mitochondrial proteins in MCF-7 (ER/PR +ve) and
MDA-MB-231 (ER/PR −ve) cells, we performed quanti-
tative proteomic analysis of mitochondrial proteins of
both cell lines in the absence and presence of TNF-α.
Mitochondrial fractions were prepared from MCF-7 and
MDA-MB-231 cells and the purity was assessed by
western blotting using selected mitochondrial marker
proteins (Tom20, UQCRC2, and SDHA) including
nuclei (PARP), cytosol (β-actin) (Fig. 1a). The mitochondrial
Fig. 1 Quantitative proteomic analysis of TNF-α regulated mitochondrial proteins in breast cancer cells. a Immunoblot analysis of isolated
mitochondria. b Molecular functions of DEPs by IPA tool. The x-axis indicates the number of proteins, red bar as upregulated, and orange bar as
downregulated proteins. c Volcano plots of DEPs displayed in the p-value (−log10) versus signal-to-noise ratio (STN). The p-value and STN were
determined by power law global error model (PLGEM) statistical analysis for label-free quantification
Shinde et al. Cancer & Metabolism            (2021) 9:19 Page 5 of 15
fraction of both MCF-7 and MDA-MB-231 showed a
high level of mitochondrial proteins of TOM20,
UQCRC2, and SDHA, whereas PARP, a marker of
nuclei, was not detected. LC-MS/MS data of MCF-7
+/- TNF-α and MDA-MB-231 +/- TNF-α were
searched against the decoy UniProt human database
and identified 1077 and 1150 mitochondrial proteins
(peptide probability > 95%; protein probability > 99%)
for MCF-7 and MDA-MB-231 cells, respectively. The
list of identified mitochondrial proteins were further
compared with mitochondrial protein databases; Mito-
Carta [21] and Gene Ontology [22]. It was observed
that 57.5% of proteins overlapped between MDA-MB-
231 and MCF-7 cells (Fig. 1c).
The quantitative statistical analysis by integrated PLGE
M-STNMAI proteomics of triplicate LC-MS/MS data
with the p-value threshold 0.01, identified 108 (62
upregulated and 49 downregulated proteins) and 111 (81
upregulated and 27 downregulated proteins) differen-
tially expressed proteins (DEPs) in MCF-7 and MDA-
MB-231, respectively (Fig. 1c), in the presence of TNF-α.
Ingenuity pathway analysis (IPA) indicated that DEPs
were involved in mitochondrial function (20%), Sirtuin
Signaling Pathway (18%), oxidative phosphorylation
(12%), protein ubiquitination (12%), and NRF2-mediated
oxidative stress (10%) in MCF-7 cells. Interestingly, IPA
analysis of DEPs in MDA-MB-231, ER/PR (−ve) cell line
showed that proteins involved in mitochondrial dysfunc-
tion, oxidative phosphorylation, sirtuin signaling, and
fatty acid β-oxidation were enriched in the presence of
TNF-α as compared to MCF-7 cell lines (Fig. 1b).
The functional annotation of the DEPs of MCF-7 and
MDA-MB-231 cell lines using IPA and hierarchical clus-
tering analysis (Mev software) (Supplementary Figure 1A)
showed a distinct cluster of genes regulating specific
pathways were modulated in the presence of TNF-α.
Cluster 1 shows DEPs between MCF-7 and MDA-MB-
231 cells in the presence of TNF-α, associated with
PPARα/RXRα activation, pyrimidine deoxyribonucleotides
de novo biosynthesis, and salvage pathways of pyrimidine
ribonucleotides. Cluster 2 shows that proteins downregu-
lated in MCF-7 and upregulated in MDA-MB-231 cells in
the presence of TNF-α, are associated with mitochondrial
function, sirtuin signaling pathway, oxidative phosphoryl-
ation, oxidative ethanol degradation, fatty acid α-oxidation,
TCA cycle, and glutamate biosynthesis. The results here
suggest that the TNF-α differentially modulates mitochon-
drial proteome in both ER/PR +ve (MCF-7) and ER/PR
−ve (MDA-MB-231) cells.
TNF-α differentially regulates the level of critical proteins
involved in mitochondrial ETC complex assembly
The remodeling of electron transport chain complexes
assembly and/or activity is important for the bioenergetic
adaptation in cancer cells; hence, we focused specifically
on the individual protein constituents of each respiratory
complex. All the known subunits of electron transport
chain (ETC) complexes including complex I, II, III, and IV
were analyzed both in MCF-7 and MDA-MB-231 in the
presence of TNF-α. The levels of NDUFS3 (a N module
component) and NDUFB1 (the component of ND4
module) significantly decreased in MCF-7 cells in the
presence of TNF-α and, however, increased in MDA-MB-
231(Fig. 2a). The levels of NDUFA11, the matrix-facing
subunit of CI increased several folds in MDA-MB-231
cells and decreased in MCF-7 in the presence of TNF-α.
This suggests that the levels of mitochondrial complex I
proteins are differentially altered in ER/PR +ve(MCF-7)
and ER/PR −ve(MDA-MB-231) cells in the presence of
TNF-α.
Complex II is the smallest mitochondrial complex and
unique as it forms a part of the TCA cycle as well as a
part of ETC hence directly linking metabolism and oxi-
dative phosphorylation; we, therefore, analyzed the levels
of complex II subunits in MCF-7 and MDA-MB-231
cells in the presence of TNF-α. MCF-7 showed increased
levels of SDHD subunit whereas other subunits SDHA
and the assembly factor, SDHAF1, decreased in the pres-
ence of TNF-α (Fig. 2b). MDA-MB-231 cells treated
with TNF-α showed no change in SDHD level whereas
the level of SDHA and SDHB increased in mitochondria.
The level of SDHAF1 was significantly high in mito-
chondria of TNF-α treated MDA-MB-231 cells as com-
pared to MCF-7.
Mitochondrial complex III is an important complex as
it accepts electrons both from complex I and complex II
via the acceptor, ubiquinone. The alteration of complex
III may lead to oxidative stress and accumulation of
oncometabolite leading to increased cell proliferation
[23]. We further analyzed the level of complex III sub-
units from the mitochondrial proteome of both MCF-7
and MDA-MB-231 cells in the presence of TNF-α.
Levels of most subunits of complex III remained same
both in MCF-7 and MDA-MB-231 in the presence of
TNF-α. Interestingly, LYRM7, a protein having the LYR
(Leucine, Tyrosine, Arginine) consensus sequence binds
to HSC20 and facilitate incorporation of Fe-S cluster
into UQCRFS1 in complex III [24, 25] during assembly
of the respiratory chain showed altered levels in both
cell lines. The level of LYRM7 significantly increased in
MCF-7 in the presence of TNF-α as compared to MDA-
MB-231 (Fig. 2c). To confirm this, the expression levels
of LYRM7 levels were also analyzed by western blotting.
LYRM7 protein levels also increased in mitochondrial
fraction of TNF-α treated MCF-7 cells whereas de-
creased in MDA-MB-231 cells (Fig. 2e). UQCRC2, a
complex III subunit also decreased in TNF-α treated
MDA-MB-231 mitochondrial fraction and correlated
Shinde et al. Cancer & Metabolism            (2021) 9:19 Page 6 of 15
with proteomics data (Fig. 2e). Similarly, BCS1L, a 419-
amino-acid chaperone protein, is a member of the family
called AAA; is localized in the inner membrane of the
mitochondria; and is presumed to facilitate the insertion
of Rieske Fe/S protein into precursors to complex III
[26]. We also analyzed the level BCS1L in mitochondrial
proteome and observed increased levels in mitochondria
of MDA-MB-231 cells in the presence of TNF-α
whereas remained unchanged in MCF-7 cells.
Complex IV subunit levels were also analyzed in mito-
chondrial fraction of both MCF-7 and MDA-MB-231.
We did not observe any significant changes in the levels
of different cytochrome-c oxidase (COX) complex
subunits. However, interestingly the assembly factors
Fig. 2 Differentially expressed proteins identified by proteomics correlates with TNF-α regulated mitochondrial function in breast cancer cells.
The raw protein abundance count of mitochondrial protein subunits from untreated and TNF-α treated triplicates from both cells were exported
and plotted as a ratio of log-fold change. The encircled proteins show the log-fold change of unique proteins in both cells. a The protein
subunits of the CI complex are clustered and color-coded into respective modules according to their function. NC represents a non-characterized
component of CI complex. b–d The log-fold change of unique proteins for CII, CIII, and CIV in both cell lines respectively (e) western blot analysis
of complex III proteins UQCRC2 and LYRM7 in MCF-7 and MDA-MB-231 in the presence of TNF-α
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required for the complex IV biogenesis were differen-
tially regulated in the presence of TNF-α in the breast
cancer cells. COX14 assembly factor plays an important
role in the translation of the COX1, the main constituent
of complex IV [27]. Its abundance decreased significantly
in the mitochondria of MDA-MB-231 as compared to
MCF-7 in the presence of TNF-α (Fig. 2d). Similarly,
another assembly factor, COX16, was downregulated in
MCF-7 cells as compared to MDA-MB-231. Altogether,
the above evidence from quantitative mitochondrial prote-
omics and immunoblotting suggests that protein levels of
specific subunits of mitochondrial ETC complexes are dif-
ferentially regulated (Supplementary figure 2) which may,
in turn, modulate the assembly and/or activity in the pres-
ence of TNF-α.
TNF-α differentially regulates mitochondrial
supercomplex assembly and activity in ER/PR +ve (MCF-7)
and ER/PR −ve (MDA-MB-231) breast cancer cells
To understand the implication of TNF-α modulated
subunits of mitochondrial ETC complexes, we analyzed
the organization and activity of ETC complexes from
both MCF-7 and MDA-MB-231 cells in the presence/
absence of TNF-α using Blue native-PAGE. We observed
that TNF-α decreased the levels, as well as the activity of
supercomplex (SC) containing complex I and complex
IV in both the cell line; however, this decrease was sig-
nificantly higher in MDA-MB-231 cells in the presence
of TNF-α (Fig. 3a). A significant decrease in individual
complex III activity was observed in MDA-MB-231 in
the presence of TNF-α compared to MCF-7 (Fig. 3b).To
further quantify the enzyme kinetics of individual ETC
complexes, we monitored the specific activity of complex
I and complex II using the spectrophotometric assay in
MCF-7 and MDA-MB-231 cells in the presence of TNF-
α either alone or combination with 2-deoxyglucose (2-
DG). 2-DG, the glucose analog, inhibits glycolysis and
decreases the growth of tumor cells, which are primarily
dependent on the glycolytic pathway. Complex I activity
significantly decreased in the presence of TNF-α in
MDA-MB-231 as compared to MCF-7 cells. The inhib-
ition of glycolysis with either 2DG alone or in combin-
ation with TNF-α increased complex I activity in MCF-7
cells. On the other hand, the activity of complex I de-
creased significantly upon inhibition of glycolysis by 2-
DG in MDA-MB-231 but remained unchanged in the
presence of both 2-DG and TNF-α (Fig. 3b). These re-
sults suggest that TNF-α negatively regulates complex I
activity in MDA-MB-231 cells which depends on gly-
colysis to maintain its activity in contrast to MCF-7.
The measurement of complex II activity revealed no
significant changes either in MCF-7 or MDA-MB-231 in
the presence of TNF-α. However, treatment with 2-DG
alone or in combination with TNF-α significantly
increased complex II activity in MDA-MB-231 suggest-
ing a compensatory response by complex II to maintain
the overall ETC function during glycolytic inhibition.
Altogether, these results indicate that TNF-α modulates
the levels of critical components of complex I, complex
III, and complex IV, hence differentially regulate the
organization and activity of ETC complexes in MDA-
MB-231 cells (ER/PR −ve) and MCF-7 cells (ER/PR +ve)
in the presence of TNF-α.
TNF-α downregulates ATP levels and enhances ROS
generation in triple-negative MDA-MB-231 cells
To investigate the effect of TNF-α regulated ETC
complexes assembly/activity on the mitochondrial bio-
energetic status of both the cells, we analyzed the level
of ATP and ROS in the presence/absence of TNF-α. In
accordance with the above results, TNF-α treatment sig-
nificantly decreased both total cellular and mitochon-
drial ATP level in MDA-MB-231 cells but not in MCF-7
cells. MCF-7 cells cultured in the presence of 2-DG in
the presence/absence of TNF-α showed a significant de-
crease in total ATP levels; however, the mitochondrial
ATP levels increased significantly under all treatment
conditions suggesting an upregulated ETC function
(Fig. 4a, b). In contrast, MDA-MB-231 cells displayed in-
creased sensitivity to a decrease in both mitochondrial
and total cellular ATP levels in the presence of TNF-α
with or without 2-DG (Fig. 4a, b). This result suggested
that MDA-MB-231 cells are strongly dependent on the
glucose-pyruvate axis for substrate oxidation and ATP
generation by OXPHOS, which is altered in the presence
of TNF-α. Similarly, both intracellular and mitochondrial
ROS levels significantly increased in both cell lines how-
ever MDA-MB-231 cells displayed an enhanced ROS
generation in the presence of TNF-α (Fig. 4c) as com-
pared to MCF-7. Altogether, these results strongly sug-
gest that TNF-α alters the mitochondrial bioenergetic
status of MDA-MB-231 cells by negatively regulating the
ETC complexes activity leading to a decrease in ATP
levels and increased ROS generation.
TNF-α modulated mitochondrial functions differentially
regulate migration and clonogenic ability of breast
cancer cells
To further investigate the role of TNF-α modulated
mitochondrial OXPHOS complex activity in regulating
tumorigenic potential of ER/PR +ve: MCF-7 and ER/PR-
ve: MDA-MB-231 cells, we analyzed the clonogenic abil-
ity in the presence/absence of TNF-α. Interestingly,
TNF-α inhibits the clonogenic ability of MCF-7 cells
whereas enhances clonogenicity of MDA-MB-231 cells
(Fig. 5b). The addition of 2DG in the presence of TNF-α
further reduced clonogenic ability of the MDA-MB-231
cells suggesting the glycolysis is essential for MDA-MB-
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231 cells. The rescue of clonogenicity was observed in
the presence of NAC (N-Acetyl cysteine), a ROS scaven-
ger in MDA-MB-231 cells, whereas it was not observed
in the MCF-7 cells. Previously, it had been observed that
electron acceptors are limited to drive ETC and other
anaplerotic reactions in cancer cells (TCA in cancer);
hence, we monitored the clonogenic ability in the pres-
ence of pyruvate. The presence of pyruvate can rescue
clonogenic ability in the presence of TNF-α in MCF-7
(Fig. 5c). Interestingly, there was no major change in
pyruvate stimulated clonogenic ability of MDA-MB-231
cells in the presence of TNF-α. We also checked the mi-
gration ability of both cells in the presence of TNF-α
and observed that TNF-α enhanced the migration ability
of MDA-MB-231 cells as compared to MCF-7 (Fig. 5a).
This is further supported by the increase in the number
of colony-forming units in culture medium supple-
mented with pyruvate. This suggests that it is not ROS
but electron acceptor ability that maintains the ratio of
NAD/NADH in the cell to drive the TCA cycle and gly-
colysis in MCF-7, whereas pyruvate, the electron ac-
ceptor, is not the limiting factor [28, 29].
Hemin is known to degrade BTB and CNC homology1
(BACH1), a haem binding transcription factor that is in-
creased in TNBC tumors and enhance mitochondrial re-
spiratory activity[30]. To further confirm the reliance of
Fig. 3 TNF-α alters the OXPHOS assembly and activity in breast cancer cells. a MCF-7 and MDA-MB-231 cells were treated with TNF-α (10 ng/μl) for 24
h. After treatment, the mitochondrial fraction was isolated and further analyzed by BN-PAGE, and in-gel enzyme staining for CI and CIV was performed.
b Complex III in-gel activity was analyzed by BN-PAGE and enzyme staining. c, d MCF-7 and MDA-MB-231 cells were treated with TNF-α (10 ng/μl) and
2-DG (10 mM) either alone or in combination for 24 h and complex I and complex II activity was measured spectrophotometrically
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MDA-MB-231 on OXPHOS activity, we checked for cell
viability of MDA-MB-231 in the presence of TNF-α in
combination with Hemin. We observed that the cell via-
bility of MDA-MB-231 cells significantly decreased in
the presence of TNF-α and Hemin (Fig. 5d). This sug-
gests that enhancing the mitochondrial proteins and
functions in MDA-MB-231 cells in the presence of
TNF-α can inhibit the triple-negative breast cancer cell
survival.
Subunit of mitochondrial complexes negatively correlates
with survival of the breast cancer patients
The TIMER database is a web resource used for sys-
temic analysis and evaluation of clinical impacts of
Fig. 4 TNF-α decreases ATP levels and increases ROS generation in MDA-MB-231 cells. a MCF-7 and MDA-MB-231 cells were treated with TNF-α
either alone or in combination with 2-DG (10 mM) and the total steady-state ATP levels were determined by the luciferase-based assay as
described in methodology. b As in a, mitochondria from respective cells were isolated upon treatment and ATP levels were measured.
Oligomycin (5 μg) treatment for 20 min was used as a positive control. c MCF-7 and MDA-MB-231 cells were treated with TNF-α. After treatment,
the cells were stained with fluorogenic ROS-sensitive dye and relative fluorescence was monitored as described in methodology. H2O2 (100 μM)
and antimycin A (10 μg) treatment for 2 h were used as a positive control
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different immune factors in diverse cancer types hence
we analyzed the correlation between TNF-α and the ex-
pression level of identified DEPs. The TIMER data
showed that increased expression of TNF-α in basal
breast cancer patients is associated with decreased gene
expression of subunits of mitochondrial complex I. This
negative correlation between TNF-α and complex I sub-
units is significantly higher in basal breast cancer patients
(Fig. 6a) and no significant correlation in luminal breast
cancer patients was observed. CIII subunits like UQCR10,
UQCRB, and UQCRQ expression were also altered in
basal breast cancer patients which showed a significant
negative correlation with TNF-α expression as compared
to luminal breasts cancer patients (Fig. 6b).
We also checked the survivability of breast cancer pa-
tients using the Kaplan-Meier survival plot analysis. The
high expression of subunits of mitochondrial complexes
like NDUFB1 (p = 0.052), SDHA (p = 0.011), and COX7B
(p = 0.064) showed an increased percentage of survival
and an increased number of survival days (Fig. 6c).
These evidence strongly suggest that TNF-α differen-
tially regulates the mitochondrial subunits in luminal
and basal breast cancer patients and determine the sur-
vival rate and span of the breast cancer patients.
Discussion
Increased level of cytokines in TME of solid tumors may
modulate mitochondrial function for metabolic adapta-
tion; however, its systemic role in the regulation of mito-
chondrial proteome and OXPHOS assembly is not well
understood. The regulation of TNF-α mediated mito-
chondrial complex assembly and its role in the regula-
tion of tumorigenic potential of different breast cancer
cell types had not been systemically investigated. To
understand the differential regulation, we here
systemically characterized mitochondrial proteome of
Fig. 5 TNF-α sensitizes cell death and decreases growth in MDA-MB-231 cells. a MCF-7 and MDA-MB-231 cells were seeded in 12 well plates and
scratch assay was performed in the presence of TNF-α. b, c MCF-7 and MDA-MB-231 cells were seeded at low denisty as described in
methodology and their ability to form colonies in the presence and absence of TNF-α,2-DG, NAC, and pyruvate was monitored. d MDA-MB-231
cells were treated with TNF-α either alone or in combination with Hemin (10 mM) and the cell viability was assessed as described in
methodology by MTT
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two different cell types MCF-7: ER/PR +ve, responsive
representing early tumor conditions, and MDA-MB-231
cells: ER/PR −ve representing aggressive and metastatic
conditions tumor cell types. There is no systemic study
monitoring the mitochondrial proteome in different
breast cancer cells which determines differential metabolic
adaptations in TME. There are some previous reports
where TRAIL, a member of the TNF-α family, modulated
total cellular proteome had been analyzed [31]; however,
total cellular proteome truly does not reflect mitochon-
drial proteins [32]. Hence, it is important to understand
the TNF-α modulated mitochondrial proteome to under-
stand the differential mitochondrial role in driving the
tumor characteristic and heterogeneity.
The high-resolution proteomics clearly showed that
TNF-α differentially modulates mitochondrial proteome
of MDA-MB-231 and MCF-7 cells leading to differential
mitochondrial function and OXPHOS capacity. Other
pathways that are differentially regulated in the presence
of TNF-α like sirtuin pathways and iron homeostasis in
MCF-7 and MDA-MB-231 cells also regulate mitochon-
drial functions; however, this can be a topic of further
investigation. The study further focused on the assembly
of mitochondrial respiratory chain complexes which are
differentially regulated in MCF-7 and MDA-MB-231
cells. The level of mitochondrial DNA encoded tran-
scripts specifically ND2 and ND3 which form part of the
core unit of the complex I, increased in MCF-7, whereas
Fig. 6 Subunit of complex negatively correlates with survival of the breast cancer patients. a, b Gene expression analysis between TNF-α and
mitochondrial CI and CIII proteins in Basal and Luminal breast cancer patients using TIMER database, respectively. c Kaplan-Meier survival plot of
BRCA patients in low/high expression of mitochondrial NDUFB1, COX7B, and SDHA genes
Shinde et al. Cancer & Metabolism            (2021) 9:19 Page 12 of 15
remaining unaltered in MDA-MB-231 cells. The levels
of NDUFS3 ( N module component) and NDUFB1 (the
component of ND4 module) were significantly decreased
in MCF-7 cells in the presence of TNF-α but, however,
increased in MDA-MB-231 suggesting that TNF-α can
differentially modulate the complex I activity which is in
consonance with in-gel activity and super complex
assembly.
Similarly, mitochondrial complex III, which can accept
electrons from both complex I and complex II through
ubiquinone is critical for mitochondrial function. The
study here showed a decrease in complex III activity
which correlates with mitochondrial proteomics data.
The level of assembly factor LYRM7 decreased in MDA-
MB-231 cells compared to MCF-7 cells. Emerging
reports suggest that binding of HSC20 (co-chaperone) to
the LYR motif of LYRM7 in a pre-assembled UQCRFS1-
LYRM7 intermediate in the mitochondrial matrix facili-
tates Fe-S cluster transfer to UQCRFS1, hence assembly
of complex III (Chaperon CI-III). This decrease in
LYRM7 in mitochondria of MDA-MB-231 cells strongly
suggests that incorporation of Fe-S complexes in mito-
chondrial electron transport chain may be modulated in
mitochondrial complex III. Hence, TNF-α modulates
flux of NADH which will shift the TCA cycle intermedi-
ates towards anaplerotic reactions in aggressive breast
tumor cells (MDA-MB-231). This is further supported
by the analysis of clonogenic abilities of the cells in the
presence of TNF-α. Interestingly, we observed that TNF-
α inhibited the clonogenic ability of MCF-7 cells which
is rescued in the presence of pyruvate suggesting that
electron acceptors are limiting factor. Pyruvate level can
be differentially regulated in MCF-7/MDA-MB-231 cells,
which is known to act as an electron acceptor and can
determine the cell proliferation. Interestingly, in MDA-
MB-231, highly metastatic cells, pyruvate is not a
limiting factor as TNF-α reprogrammed the activity of
OXPHOS for anaplerotic reaction, as we observed pyru-
vate supplementation showed no major effect on cell
proliferation or clonogenic abilities of the cells. This ob-
servation further supported as we observed a high level
of pyruvate in MDA-MB-231 cells as compared to MCF-
7 cells (unpublished observation).
The decrease in complex I/III activity may increase the
level of ROS in triple-negative aggressive breast cancer
cells which may act as mitohormetic response rather
than cell death. This observation is in consonance with a
recent report where it had been observed that an in-
creased level of ROS in selected aggressive breast cancer
cells from TNBC patients can induce mitohormetic
response in modulating nuclear genes which help to
survive in the hostile tumor microenvironment.
The overall decrease in the mitochondrial proteins and
complex activity in MDA-MB-231 is supported by a
recent study where BTB and CNC homology1 (BACH1),
a haem binding transcription factor increased in tumors
from patients with TNBC which negatively regulates
transcription of electron transport chain (ETC) genes
[30]. It was observed that enhancing the reliance of
breast cancer cells to mitochondrial functions by modu-
lating the transcription factor BACH1 using hemin
which initiates degradation of BACH1, sensitizes the
cancer cells to metformin. In our study, the TIMER
webserver showed a negative correlation of CI and CIII
subunits with TNF-α in basal breast cancer patients.
This correlates with the decrease in complex assembly
and activity in MDA-MB-231 in the presence of TNF-α.
Further, the survivability of breast cancer patients
also correlates with the expression of mitochondrial
complexes.
Conclusion
In conclusion, the subcellular proteomics identifies the
differential behavior of the ER/PR +ve and ER/PR −ve
breast cancer cells in response to TNF-α. The evidences
here clearly suggest that TNF-α modulates metabolism
differentially in ER/PR +ve and ER/PR −ve breast cancer
cells by modulating the levels of critical assembly factors
and subunits involved in mitochondrial respiratory chain
supercomplexes. TNF-α modulated metabolic reprogram-
ming favors survival and proliferation of more aggressive
ER/PR −ve breast cancer cells. This study identified novel
assembly factors as possible therapeutic target to prevent
the progression of aggressive breast cancer cells hence the
survival of the breast cancer patients.
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